A Study to Evaluate LY3154207 on the Brain of Healthy Participants

Lilly

Status and phase: Completed; Phase 1

Conditions: Healthy

Treatments: Drug: Placebo; Drug: LY3154207

Study type: Interventional

Funder types: Industry

Identifiers

NCT04258826

I7S-MC-HBEM (Other Identifier)

17294

Details and patient eligibility

About

The purpose of this study is to learn more about how LY3154207 affects the brain of healthy participants by using magnetic resonance imaging. The study will last up to about nine weeks for each participant and may include up to four visits to the study center.

Enrollment: 16 patients

Sex: All

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

-Overtly healthy males and non-childbearing females, as determined through medical history and physical examination

Exclusion criteria

• Have known or ongoing psychiatric disorders
• Have contraindications to magnetic resonance imaging (MRI)

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: Double Blind

---

16 participants in 2 patient groups, including a placebo group

LY3154207

Experimental group

Description:

LY3154207 administered orally in one of two study periods.

Treatment:

Drug: LY3154207

Placebo

Placebo Comparator group

Description:

Placebo administered orally in one of two study periods.

Treatment:

Drug: Placebo